Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

[Protocol for tizanidine use in infantile cerebral palsy].

Palazón García R, Benavente Valdepeñas A, Arroyo Riaño O.

An Pediatr (Barc). 2008 May;68(5):511-5. Spanish.

2.
3.

[The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].

Vásquez-Briceño A, Arellano-Saldaña ME, León-Hernández SR, Morales-Osorio MG.

Rev Neurol. 2006 Aug 1-15;43(3):132-6. Spanish.

5.

Pharmacologic interventions for reducing spasticity in cerebral palsy.

Patel DR, Soyode O.

Indian J Pediatr. 2005 Oct;72(10):869-72. Review.

PMID:
16272661
6.

Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Henney HR 3rd, Chez M.

Paediatr Drugs. 2009;11(6):397-406. doi: 10.2165/11316090-000000000-00000.

PMID:
19877725
7.

Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.

Vakhapova V, Auriel E, Karni A.

Clin Neuropharmacol. 2010 May;33(3):151-4. doi: 10.1097/WNF.0b013e3181daad7d.

PMID:
20502134
8.

[Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia].

Tanaka H, Fukuda I, Miyamoto A, Oka R, Cho K, Fujieda K.

No To Hattatsu. 2004 Nov;36(6):455-60. Japanese.

PMID:
15560387
9.

Oral baclofen and clonidine for treatment of spasticity in children.

Lubsch L, Habersang R, Haase M, Luedtke S.

J Child Neurol. 2006 Dec;21(12):1090-2.

PMID:
17156708
10.

Pharmacotherapy of spasticity in children with cerebral palsy.

Chung CY, Chen CL, Wong AM.

J Formos Med Assoc. 2011 Apr;110(4):215-22. doi: 10.1016/S0929-6646(11)60033-8. Review.

12.

Continuous intrathecal baclofen infusion for children with cerebral palsy: a pilot study.

Scheinberg A, O'Flaherty S, Chaseling R, Dexter M.

J Paediatr Child Health. 2001 Jun;37(3):283-8.

PMID:
11468046
13.

A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.

Medici M, Pebet M, Ciblis D.

Curr Med Res Opin. 1989;11(6):398-407.

PMID:
2651016
14.
15.

Use of intramuscular botulinum toxin in Malaysian children with cerebral palsy.

Khoo TB, Yusniza MY, Chern PM.

Med J Malaysia. 2007 Mar;62(1):3-5.

16.

Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.

Bass B, Weinshenker B, Rice GP, Noseworthy JH, Cameron MG, Hader W, Bouchard S, Ebers GC.

Can J Neurol Sci. 1988 Feb;15(1):15-9.

PMID:
3345456
17.

Modified release tizanidine in the treatment of spasticity.

Chantraine A, Van Ouwenaller C.

J Int Med Res. 1988 Nov-Dec;16(6):459-65.

PMID:
3234596
18.

Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.

Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D.

Curr Med Res Opin. 1988;10(10):699-708.

PMID:
3286128
19.

[Botulinum toxin in the management of spastic hip adductors in non-ambulatory cerebral palsy children].

Deleplanque B, Lagueny A, Flurin V, Arnaud C, Pedespan JM, Fontan D, Pontallier JR.

Rev Chir Orthop Reparatrice Appar Mot. 2002 May;88(3):279-85. French.

PMID:
12037484
20.

A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.

Kamen L, Henney HR 3rd, Runyan JD.

Curr Med Res Opin. 2008 Feb;24(2):425-39. doi: 10.1185/030079908X261113 . Review.

PMID:
18167175
Items per page

Supplemental Content

Support Center